In vivo effects of anacetrapib on preβ HDL: Improvement in HDL remodeling without effects on cholesterol absorption

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2858-2865

  Wang, Sheng Ping ^a   Daniels, Erin ^a   Chen, Ying ^a   Castro Perez, Jose ^a   Zhou, Haihong ^a   Akinsanya, Karen O ^a   Previs, Stephen F ^a   Roddy, Thomas P ^a   Johns, Douglas G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anacetrapib; Apolipoprotein A1; Cholesteryl ester transfer protein; Dalcetrapib; High density lipoprotein

Indexed keywords

ANACETRAPIB; CHOLESTEROL; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRE BETA HIGH DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CHOLESTEROL ABSORPTION; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DYSLIPIDEMIA; GASTROINTESTINAL ABSORPTION; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANACETRAPIB; APOLIPOPROTEIN A1; CHOLESTERYL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZETIDINES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CRICETINAE; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; INTESTINAL ABSORPTION; MALE; MESOCRICETUS; OXAZOLIDINONES; SULFHYDRYL COMPOUNDS;

EID: 84884166812     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M041541     Document Type: Article

References (33)

1. Davidson, M. H., J. M. McKenney, C. L. Shear, and J. H. Revkin. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48: 1774-1781.
2. McKenney, J. M., M. H. Davidson, C. L. Shear, and J. H. Revkin. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average highdensity lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48: 1782-1790.
3. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
4. Forrest, M. J., D. Bloomfield, R. J. Briscoe, R. N. Brown, A. M. Cumiskey, J. Ehrhart, J. C. Hershey, W. J. Keller, X. Ma, H. E. McPherson, et al. 2008. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154: 1465-1473.
5. DePasquale, M., G. Cadelina, D. Knight, W. Loging, S. Winter, E. Blasi, D. Perry, and J. Keiser. 2009. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors. Drug Dev. Res. 70: 35-48.
6. Hu, X., J. D. Dietz, C. S. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. D. Yuan, D. A. Perry, and J. Keiser. 2009. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 150: 2211-2219.
7. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
8. Landmesser, U., A. von Eckardstein, J. J. Kastelein, J. Deanfield, and T. G. Lüscher. 2012. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur. Heart J. 33: 1712-1715.
9. Krishna, R., A. J. Bergman, B. Jin, M. Fallon, J. Cote, P. Van Hoydonck, T. Laethem, I. N. Gendrano 3rd, K. Van Dyck, D. Hilliard, et al. 2008. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84: 679-683.
10. Bloomfield, D., G. L. Carlson, A. Sapre, D. Tribble, J. M. McKenney, W. T. Littlejohn 3rd, C. M. Sisk, Y. Mitchel, and R. C. Pasternak. 2009. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157: 352-360.
11. Cannon, C. P., S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al. 2010. Safety of anacetrapib in patients with or at high risk for coronary orally administered D 6 -cholesterol heart disease. N. Engl. J. Med. 363: 2406-2415.
12. Yvan-Charvet, L., J. Kling, T. Pagler, H. Li, B. Hubbard, T. Fisher, C. P. Sparrow, A. K. Taggart, and A. R. Tall. 2010. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30: 1430-1438.
13. Castro-Perez, J., F. Briand, K. Gagen, S. P. Wang, Y. Chen, D. G. McLaren, V. Shah, R. U. Vreeken, T. Hankemeier, T. Sulpice, et al. 2011. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. 52: 1965-1973.
14. Ranalletta, M., K. K. Bierilo, Y. Chen, D. Milot, Q. Chen, E. Tung, C. Houde, N. H. Elowe, M. Garcia-Calvo, G. Porter, et al. 2010. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51: 2739-2752.
15. Asztalos, B. F., C. H. Sloop, L. Wong, and P. S. Roheim. 1993. Twodimensional electrophoresis of plasma lipoproteins: recognition of new apoA-I-containing subpopulations. Biochim. Biophys. Acta. 1169: 291-300.
16. Lassman, M. E., T. M. McLaughlin, E. P. Somers, A. C. Stefanni, Z. Chen, B. A. Murphy, K. K. Bierilo, A. M. Flattery, K. K. Wong, J. M. Castro-Perez, et al. 2012. A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 26: 101-108.
17. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissue. J. Biol. Chem. 226: 497-509.
18. Shah, V., K. Herath, S. F. Previs, B. K. Hubbard, and T. P. Roddy. 2010. Headspace analyses of acetone: a rapid method for measuring the 2H-labeling of water. Anal. Biochem. 404: 235-237.
19. Previs, S. F., A. Mahsut, A. Kulick, K. Dunn, G. Andrews-Kelly, C. Johnson, G. Bhat, K. Herath, P. L. Miller, S. P. Wang, et al. 2011. Quantifying cholesterol synthesis in vivo using (2)H(2)O: enabling back-to-back studies in the same subject. J. Lipid Res. 52: 1420-1428.
20. Turley, S. D., M. W. Herndon, and J. M. Dietschy. 1994. Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J. Lipid Res. 35: 328-339.
21. Zilversmit, D. B., and L. B. Hughes. 1974. Validation of a dualisotope plasma ratio method for measurement of cholesterol absorption in rats. J. Lipid Res. 15: 465-473.
22. Van Heek, M., C. F. France, D. S. Compton, R. L. McLeod, N. P. Yumibe, K. B. Alton, E. J. Sybertz, and H. R. Davis, Jr. 1997. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther. 283: 157-163.
23. van Heek, M., T. M. Austin, C. Farley, J. A. Cook, G. G. Tetzloff, and H. R. Davis. 2001. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes. 50: 1330-1335.
24. Barter, P. J., and K. A. Rye. 1996. Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. 7: 82-87.
25. Liang, H. Q., K. A. Rye, and P. J. Barter. 1994. Dissociation of lipidfree apolipoprotein A-I from high density lipoproteins. J. Lipid Res. 35: 1187-1199.
26. Brousseau, M. E., M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Björkhem, B. Angelin, et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25: 1057-1064.
27. Matsuura, F., N. Wang, W. Chen, X. C. Jiang, and A. R. Tall. 2006. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1- dependent pathway. J. Clin. Invest. 116: 1435-1442.
28. Lie, J., R. de Crom, M. Jauhiainen, T. van Gent, R. van Haperen, L. Scheek, H. Jansen, C. Ehnholm, and A. van Tol. 2001. Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins. Biochem. J. 360: 379-385.
29. Lusa, S., M. Jauhiainen, J. Metso, P. Somerharju, and C. Ehnholm. 1996. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem. J. 313: 275-282.
30. Asztalos, B. F., and P. S. Roheim. 1995. Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1419-1423.
31. Niesor, E. J., C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, H. Matile, G. Schmid, R. G. Clerc, E. Chaput, D. Blum-Kaelin, et al. 2010. Modulating cholesteryl ester transfer protein activity maintains efficient pre- HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51: 3443-3454.
32. Stein, E. A., E. M. Roth, J. M. Rhyne, T. Burgess, D. Kallend, and J. G. Robinson. 2010. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur. Heart J. 31: 480-488.
33. Niesor, E. J., E. Chaput, A. Staempfli, D. Blum, M. Derks, and D. Kallend. 2011. Effect of dalcetrapib, a CETP modulator, on noncholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis. 219: 761-767.